A rectal submucosal tumour is defined as a mass-like protrusion in the rectum covered by normal mucosa. It comprises a variety of benign and malignant tumours that originate from the rectal wall or outside the rectum. Full characterisation by endoscopy or endoscopic biopsy is often difficult due to its deep location. Magnetic resonance imaging (MRI) can provide information about the origin, internal composition, and local extent of the tumour. Radiologists should be familiar with the types and MRI features of rectal submucosal tumours to facilitate accurate diagnosis and guide management.
tumours but not their characteristics. Transrectal ultrasonography can localise the specific mural layer of origin, but has limitations in the evaluation of large tumours, high rectal tumours, relationship of the tumour with the anal sphincter complex, and other pelvic organs. The diagnostic accuracy of transrectal ultrasonography-guided fine-needle aspiration / biopsy for rectal subepithelial tumours has been reported to be only 50%. 1 Magnetic resonance imaging (MRI) has a high softtissue contrast and multiplanar capability and enables discrimination of different layers of the rectal wall and evaluation of the origin and internal composition of rectal submucosal tumours. MRI is the investigative tool of choice for the complex anatomy of the pelvis and the relationship of tumours with the pelvic floor, sphincter complex, and adjacent organs to facilitate surgical planning.
This review aimed to highlight the common types of rectal submucosal tumours encountered in clinical practice and their MRI features in order to facilitate accurate diagnosis and guide management.
MAGNEt RESONANCE iMAGiNG PROtOCOl
An MRI protocol to evaluate rectal submucosal tumours includes axial T1-weighted and T2-weighted turbo spin-echo (TSE) imaging of the pelvis, T1-weighted 3D gradient-echo fat-suppressed imaging of the pelvis, sagittal and oblique axial 3-mm high-resolution T2-weighted TSE sequences of the rectum, coronal 3-mm high-resolution T2-weighted TSE sequences parallel to the anal canal for low-lying tumours, axial T1-weighted 3D gradient-echo fat-suppressed imaging of the pelvis following intravenous injection of gadolinium-based contrast material, diffusion-weighted imaging of the pelvis with b values of 0, 500, and 1000 sec/mm 2 , and reconstruction of an apparent diffusion coefficient map. A phased array coil is used; an intravenous anti-spasmolytic is routinely administered unless contraindicated. Prior rectal preparation is not required.
intramural Origin
Neuroendocrine Tumour Approximately 34% of neuroendocrine tumours of the gastrointestinal tract (previously known as carcinoid tumours) occur in the rectum, mostly the midrectum. 2, 3 They develop from the muscularis mucosa or submucosal layer and are commonly circumscribed. 2, 4 Approximately 79% of such tumours are <1 cm and only 5% are >2 cm. Most patients are asymptomatic and tumour detection is often incidental during routine endoscopy for unrelated symptoms.
Rectal neuroendocrine tumours have a good prognosis. Tumour size and micro-invasiveness are the most important prognostic factors. 4 Risk factors for metastatic disease include tumour size, muscularis propria invasion, proliferative index, and lymphovascular and perineural invasion. 3 Patients with a larger tumour are often referred for further imaging before excision. Patients with unfavourable histology after excision are referred for MRI to exclude metastasis in the mesorectum. Due to its origin in the superficial layers of the rectal wall, rectal neuroendocrine tumours typically appear as a small superficial submucosal mass causing endoluminal bulging but without a significant exophytic component. The tumour is usually isointense on T1-weighted images and hyperintense on T2-weighted images, with moderate-to-intense contrast enhancement ( Figure 1 ). [4] [5] [6] In pancreatic neuroendocrine tumours, lower apparent diffusion coefficient values correlate with higher histological grades. 7, 8 Nonetheless, such correlation has not been investigated for primary gastrointestinal neuroendocrine tumours.
Gastrointestinal Stromal Tumour
GIST is the most common mesenchymal neoplasm of the gastrointestinal tract. It is defined by the expression of KIT (CD117), a tyrosine kinase growth factor receptor, that distinguishes GISTs from other mesenchymal neoplasms (such as leiomyoma, leiomyosarcoma, schwannoma, and neurofibroma) and determines the appropriateness of KIT-inhibitor therapy. 9 The most frequent sites of GIST are the stomach (60-70%) and small intestine (20-25%); only 5% of GISTs arise in the rectum. 4 Most GISTs arise within the muscularis propria of the intestinal wall and thus have an exophytic growth pattern and manifest as a dominant mass outside the organ of origin without invasion into adjacent organs ( Figure 2 ).
9 Dominant intramural and intraluminal masses are less common radiological manifestations. 9 On MRI, GISTs are usually seen as an eccentric mural mass with well-circumscribed margins. Compared with muscle, GISTs show T1 hypointensity and mild T2 hyperintensity, with moderate heterogeneous gadolinium contrast enhancement. Mucosal ulceration may be seen. Restricted diffusion is a common feature due to the high cellularity of the tumour ( Figure 3 ). There is a negative linear correlation between the mean apparent diffusion coefficient values and the malignancy risk of GISTs. 10 The prevalence of intra-tumoural cystic change that indicates tumour necrosis is higher in the moderate-to-high risk group than in the very low-to-low risk group. 10 Higher-risk GISTs may metastasise to the liver and peritoneum, but lymph node metastasis is rare (<3%).
11 Hence, lymphadenopathy in the mesorectum is not a common feature of rectal GIST.
Schwannoma
In the gastrointestinal tract, schwannomas mostly occur in the oesophagus and stomach, followed by the small intestine and appendix. Schwannomas of the colon and rectum are rare. 4 The ratio of GIST to colonic schwannoma has been reported to be 8-100:1.
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O n M R I , s c h w a n n o m a s a r e t y p i c a l l y a w e l lcircumscribed submucosal mass with T2 hyperintensity representing the myxoid component. Multiple s c h w a n n o m a s m a y b e e n c o u n t e r e d . C o n t r a s t enhancement can be heterogeneous if the tumour is In contrast, schwannomas are exclusively accompanied by enlarged lymph nodes; the underlying reason might be the presence of lymphoid cuffing around the tumour. 12 Schwannoma is a differential diagnosis of rectal submucosal tumours when a submucosal mass is detected with enlarged lymph nodes in the mesorectum (Figure 4 ). 
Melanoma
Melanoma is a highly aggressive malignant tumour that rarely arises in the anorectum. 13 Melanomas originate from melanocytes that are cells derived from the embryological neural crest. During foetal development, melanocytes migrate throughout the body, primarily to the skin, but a small number also reside in the eyes (retina and uveal tract) and mucosal surfaces. Cutaneous melanomas account for >90% of all melanomas and mucosal melanomas for <2%.
14 In the anorectal region, a primary melanoma arises from melanocytes at the anal transitional zone between columnar epithelium and squamous epithelium, and progresses upwards from the submucosa towards the rectum. 15 Therefore, most tumours arise at or slightly above the dentate line and rarely in the rectal location. Anorectal melanoma can present as a mucosal or submucosal mass. In the early stage of disease, they are often misdiagnosed as thrombosed haemorrhoids or skin tag. In most cases, they manifest late as bulky intraluminal masses without causing obstruction and are associated with perirectal infiltration and nodal metastases. 16 Melanoma cells may carry melanin pigment that shortens the T1 relaxation time due to the paramagnetic element. Melanoma also has a propensity to bleed. These account for the classic T1 hyperintensity in <50% of melanomas. Nonetheless, T1 hyperintensity is not shown in melanomas with <10% melanin-containing cells, and up to one-third of anorectal melanomas are amelanocytic ( Figure 5 ). On T2-weighted images, melanomas are typically hypointense but may contain mixed signal intensity. These are hypercellular and hypervascular tumours, and hence restricted diffusion and contrast enhancement are typically present. 16, 17 Regional nodal metastases occur in about half of the cases at diagnosis. 18, 19 The prognosis of anorectal melanoma is poor. Surgery remains the standard treatment, whereas systemic therapy is often palliative. 18 Due to its almost invariable involvement of the anorectal junction and high chance of local infiltration, MRI is important in the evaluation of local extent and operability.
Metastatic Spread to the Rectum
Metastasis from a distant primary tumour to the rectum is extremely rare. It can occur by direct invasion of metastatic deposits in the pelvis such as by lymph nodes, serosal metastatic deposits in peritoneal carcinomatosis, or via haematogenous spread. Nearly all malignancies have the potential to metastasise to the subperitoneal or peritoneal space, most commonly gastrointestinal and ovarian primary carcinomas. 20 Serosal metastatic deposits may be found in the upper and mid rectum that is in contact with the anterior peritoneal reflection (Figure 6 ). In a multi-centre study of approximately 10,000 patients with malignant colorectal tumours, only 35 patients (0.3%) had metastases through haematogenous spread to the colon or rectum from distant primary tumours, with the breast being the most common primary site, followed by melanoma, lung, bone and soft-tissue sarcoma, and kidney. 21 Metastatic spread to the rectum indicates a latestage of the disease and a poor prognosis, but it may occur up to 10 years after diagnosis of the primary tumour, particularly in patients with primary renal cell carcinoma. 22 MRI allows evaluation of the local extent and scrutiny for other metastatic involvement in the pelvis. MRI features of rectal metastasis are similar to those of primary tumours. Radiologists should be aware of this, especially in patients with a history of primary malignancies.
Extramural Origin

Endometriosis
Endometriosis is defined as the presence of functional endometrial glands and stroma outside the uterine cavity. Deep pelvic endometriosis, also known as deepinfiltrating endometriosis, is defined as subperitoneal invasion by endometriotic tumour that exceeds 5 mm. 23 It can affect various fibromuscular pelvic structures, with the recto-vaginal septum and uterosacral ligaments being most common (69.2%), followed by the alimentary tract (9.9%), with the rectosigmoid colon being the most common bowel segment. 23 U n l i k e s u p e r f i c i a l e n d o m e t r i o s i s o r o v a r i a n endometriosis, deep pelvic endometriosis is often associated with pelvic pain, dyspareunia, and infertility. It is a differential diagnosis of rectal submucosal tumour if a submucosal rectal mass is seen in a symptomatic premenopausal woman. Endometriotic tumour manifests as an irregular, infiltrative, T2-hypointense mass with discrete fibrotic reaction due to chronic repetitive bleeding and scarring. It often penetrates the muscularis propria and invades the submucosa involving at least 40% of the circumference in the anterior rectal wall. On T2-weighted images, a 'mushroom cap' sign is indicative of solid invasive endometriosis of the rectosigmoid colon. 24 The low-signal intensity of the mushroom base is attributed to hypertrophy and fibrosis of the muscularis propria, whereas the high-signal intensity of the cap represents the mucosa and submucosa that are displaced into the bowel lumen. Small internal cystic foci represent ectopic endometrial glands, but their visualisation depends on location and the patient's immune response. Hyperintensity on T1-weighted, fat-suppressed images indicates subacute blood and is specific for endometriosis ( Figure 7) . 25 Such finding is less common in deep pelvic endometriosis because the surrounding fibrosis and muscular hypertrophy minimise cyclical bleeding in the ectopic endometrial glands. The degree of contrast enhancement is variable and heterogeneous, depending on the glandular and fibrotic component of the tumour.
Tailgut Cyst
Tailgut cyst (retrorectal cystic hamartoma) is a rare developmental tumour thought to arise from vestiges of an embryonic hindgut and is found in the retrorectal (presacral) space. 26 It is more commonly found in middle-aged women. 26 Tailgut cyst usually presents as a multilocular cystic tumour with multiple small cysts clustering adjacent to a main cyst, giving rise to a honeycomb appearance. It is typically located in the retrorectal space above the pelvic floor although extension through the levator muscle to the ischioanal fossa may occur. 27, 28 It adheres to the sacrum and rectum but does not communicate with the rectal lumen. Erosion of the sacrococcygeal bone may occur. 28 The signal intensities on T1-and T2-weighted images vary according to the protein, mucin, and blood content of the cysts. In most tumours, the dominant cysts are hyperintense on T1-weighted images, with reference to the pelvic musculature (Figure 8) . Infection, fistulation, recurrence after excision, and malignant degeneration are potential complications. The presence of enhancing solid components should raise the suspicion of malignant transformation although this is rare. 4, 26, 28, 29 Differential diagnoses of a retrorectal cystic mass include mature cystic teratoma, epidermoid cyst, dermoid cyst, rectal duplication cyst, and anterior sacral meningocoele (that are usually unilocular), as well as tailgut cyst and cystic lymphangioma (that are usually multilocular); there is substantial overlap among these entities. 4, 26 Direct Rectal Invasion by Extra-colonic Pelvic Tumour Primary tumours arising from other pelvic organs (such as the uterus, ovary, or prostate) may invade the rectum. On endoscopy, it is difficult to differentiate among extrinsic tumours invading the rectum, extrinsic tumours indenting but not invading the rectal wall, and primary rectal intramural tumours. The primary role of MRI in this entity is to identify the primary tumour site (Figures 9 and 10) . 
